Ozempic & GLP-1 Lawsuit in Pennsylvania
Last Updated: April 1, 2026
Pennsylvania is a major pharmaceutical litigation venue, with Philadelphia historically serving as one of the most significant mass tort jurisdictions in the country through its specialized Complex Litigation Center. The state's 13 million residents and two-year statute of limitations mean prompt action is necessary for Depo-Provera and GLP-1 claims. Pennsylvania's three federal districts and well-developed product liability jurisprudence make it a critical state for pharmaceutical injury litigation.
GLP-1 medications including Ozempic, Wegovy, Mounjaro, and Trulicity have been linked to serious injuries including gastroparesis, vision loss (NAION), pancreatitis, gallbladder disease, and bowel obstruction. Over 3,400 lawsuits are pending in federal court. Pennsylvania residents who were injured may qualify for compensation. The product liability statute of limitations in Pennsylvania is 2 years. Attorneys handle these cases on a contingency fee basis — no cost unless you win.
GLP-1 Medication Lawsuits in Pennsylvania
GLP-1 receptor agonist medications — including Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, and Trulicity — were prescribed to millions of Pennsylvania residents for type 2 diabetes and weight management. While these drugs were marketed as breakthrough treatments, growing evidence has linked them to severe and sometimes permanent injuries that the manufacturers allegedly failed to adequately disclose.
The federal litigation against Novo Nordisk and Eli Lilly has been consolidated into multidistrict litigation (MDL 3094) in the Eastern District of Pennsylvania. Pennsylvania residents who suffered injuries from GLP-1 medications can file claims that join this consolidated proceeding, benefiting from coordinated pretrial discovery while retaining their individual right to trial.
The lawsuits allege that the manufacturers knew their drugs could cause serious gastrointestinal injuries — including stomach paralysis, bowel blockages, and pancreatic inflammation — as well as vision loss, yet they prioritized profits over patient safety by failing to warn prescribers and patients about the true scope of these risks. For Pennsylvania residents, the stakes are high: these injuries can be permanent, require multiple surgeries, and fundamentally alter quality of life.
As the litigation progresses, early bellwether trials are expected to set the stage for broader settlement discussions. Pennsylvania residents who have been injured should evaluate their claims now, before filing deadlines expire.
Pennsylvania legal landscape: Pennsylvania applies modified comparative fault with a 50% bar and follows strict liability under Section 402A of the Restatement (Second) of Torts. Notably, Pennsylvania does not recognize the risk-utility test for design defects in strict liability — the plaintiff must show the product was defective and unreasonably dangerous under a consumer expectations test. Residents in Philadelphia, Pittsburgh, Allentown, Erie, and Reading and surrounding areas should consult with an attorney experienced in pharmaceutical litigation to evaluate their potential claim.
GLP-1 Injuries Covered in Pennsylvania
Pennsylvania residents may file claims for the following GLP-1 medication injuries. Click on each injury to learn more about state-specific legal options:
Gastroparesis
Stomach paralysis causing severe nausea, vomiting, and inability to digest food normally
Learn more about gastroparesis claims in Pennsylvania →
Vision Loss (NAION)
Non-arteritic anterior ischemic optic neuropathy causing sudden, painless vision loss
Learn more about vision loss (naion) claims in Pennsylvania →
Pancreatitis
Inflammation of the pancreas causing severe abdominal pain
Learn more about pancreatitis claims in Pennsylvania →
Gallbladder Disease
Gallstones, cholecystitis, or other gallbladder complications requiring surgery
Learn more about gallbladder disease claims in Pennsylvania →
Bowel Obstruction
Blockage in the small or large intestine preventing food and fluids from passing
Learn more about bowel obstruction claims in Pennsylvania →
Pennsylvania Statute of Limitations for GLP-1 Claims
The statute of limitations determines how long Pennsylvania residents have to file a GLP-1 injury lawsuit. In Pennsylvania, the product liability statute of limitations is 2 years, and the personal injury statute of limitations is 2 years.
Pennsylvania applies the discovery rule to pharmaceutical injury claims. This means the filing deadline may begin running from the date you discovered — or reasonably should have discovered — that your injury was caused by a GLP-1 medication, not the date you first took the drug. Because the link between GLP-1 medications and certain injuries is still emerging in the scientific literature, many Pennsylvania residents may have more time than they realize to file.
Every case is different. Factors such as when you were first prescribed the medication, when your injury was diagnosed, and when you became aware of the potential connection all affect your specific deadline. A free case review can help clarify your timeline.
Personal Injury SOL
2 years
Product Liability SOL
2 years
Discovery Rule
Yes
Do You Qualify in Pennsylvania?
Pennsylvania residents may be eligible to file a GLP-1 injury claim if the following apply:
Used a GLP-1 Medication
You were prescribed and used Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, Trulicity, or another GLP-1 receptor agonist medication while residing in Pennsylvania or another state.
Developed a Qualifying Injury
You were diagnosed with gastroparesis, vision loss (NAION), pancreatitis, gallbladder disease, or bowel obstruction after starting the medication.
Have Medical Documentation
You have medical records documenting your diagnosis. For gastroparesis claims, a gastric emptying study is strongly recommended but not required to begin the process.
Not Already Represented
You are not currently represented by another attorney for this specific claim. If you are unsure, your case review can help clarify.
Pennsylvania GLP-1 Lawsuit FAQ
What GLP-1 medications are involved in the Pennsylvania lawsuits?
The GLP-1 litigation covers several medications including Ozempic (semaglutide), Wegovy (semaglutide), Mounjaro (tirzepatide), Rybelsus (oral semaglutide), Saxenda (liraglutide), and Trulicity (dulaglutide). Pennsylvania residents who used any of these medications and suffered serious injuries may be eligible to file a claim. These drugs are manufactured by Novo Nordisk and Eli Lilly.
What is the statute of limitations for an Ozempic lawsuit in Pennsylvania?
In Pennsylvania, the statute of limitations for product liability claims is 2 years. Pennsylvania applies the discovery rule, which means the filing deadline may start from the date you discovered or should have discovered that your injury was caused by a GLP-1 medication, rather than the date you first took the drug. Given the evolving science around GLP-1 injuries, many residents may still have time to file.
What injuries qualify for a GLP-1 lawsuit in Pennsylvania?
Qualifying injuries include gastroparesis (stomach paralysis), vision loss caused by non-arteritic anterior ischemic optic neuropathy (NAION), pancreatitis, gallbladder disease requiring surgery, and bowel obstruction. All of these injuries must have developed after starting a GLP-1 medication. Pennsylvania residents who have experienced any of these conditions should seek a free case evaluation to determine eligibility.
How are GLP-1 lawsuit cases filed in Pennsylvania?
GLP-1 injury claims in Pennsylvania can be filed in state court through the Pennsylvania Courts of Common Pleas or in federal court. Many federal cases are being consolidated into multidistrict litigation (MDL 3094) for pretrial proceedings. The federal districts serving Pennsylvania include the Eastern District of Pennsylvania, Middle District of Pennsylvania, Western District of Pennsylvania. An experienced attorney will determine the best venue for your specific case.
What compensation can Pennsylvania residents receive from a GLP-1 lawsuit?
Pennsylvania residents who qualify may recover compensation for medical expenses (hospitalization, surgery, ongoing treatment), lost wages and diminished earning capacity, pain and suffering, emotional distress, and diminished quality of life. The specific amount depends on the severity of your injury, required medical treatment, and impact on your daily life and ability to work.
Is there any cost to file a GLP-1 injury claim in Pennsylvania?
There is no upfront cost. Attorneys handling GLP-1 injury cases in Pennsylvania work on a contingency fee basis — they only get paid if you receive compensation. NuLegal's initial case review is completely free with no obligation to proceed. You will never be asked to pay out of pocket.
Related Resources
Pennsylvania Residents: Act Now
The product liability statute of limitations in Pennsylvania is 2 years. Get a free, no-obligation case review today to protect your rights and find out if you qualify for compensation.
Free Case ReviewAdvertisement
Disclosure: NuLegal operates as a legal referral service. Attorney Ashkaan Hassan evaluates claims and refers qualified cases to specialized trial firms, earning a referral fee from the attorney's share of any recovery. Clients never pay out of pocket.